Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells

Blood. 2012 Aug 16;120(7):1422-31. doi: 10.1182/blood-2012-03-419747. Epub 2012 Jul 11.

Abstract

TLR agonists initiate a rapid activation program in dendritic cells (DCs) that requires support from metabolic and bioenergetic resources. We found previously that TLR signaling promotes aerobic glycolysis and a decline in oxidative phosphorylation (OXHPOS) and that glucose restriction prevents activation and leads to premature cell death. However, it remained unclear why the decrease in OXPHOS occurs under these circumstances. Using real-time metabolic flux analysis, in the present study, we show that mitochondrial activity is lost progressively after activation by TLR agonists in inflammatory blood monocyte-derived DCs that express inducible NO synthase. We found that this is because of inhibition of OXPHOS by NO and that the switch to glycolysis is a survival response that serves to maintain ATP levels when OXPHOS is inhibited. Our data identify NO as a profound metabolic regulator in inflammatory monocyte-derived DCs.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate / metabolism
  • Animals
  • Cell Death / drug effects
  • Cell Respiration / drug effects
  • Cell Survival / drug effects
  • Dendritic Cells / drug effects
  • Dendritic Cells / enzymology
  • Dendritic Cells / metabolism*
  • Dendritic Cells / pathology*
  • Glycolysis* / drug effects
  • Inflammation / enzymology
  • Inflammation / pathology*
  • Lipopolysaccharides / pharmacology
  • Mice
  • Mice, Inbred C57BL
  • Mitochondria / drug effects
  • Mitochondria / metabolism
  • Models, Immunological
  • Monocytes / pathology
  • Nitric Oxide / biosynthesis*
  • Nitric Oxide Synthase Type II / metabolism
  • Time Factors
  • Toll-Like Receptors / metabolism

Substances

  • Lipopolysaccharides
  • Toll-Like Receptors
  • Nitric Oxide
  • Adenosine Triphosphate
  • Nitric Oxide Synthase Type II